Jose Carmona - 31 Jan 2022 Form 4 Insider Report for Rubius Therapeutics, Inc.

Reporting relationship
Chief Financial Officer
Issuer ticker
N/A
Reported as of
31 Jan 2022
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
01 Feb 2022, 20:20:24 UTC
Next SEC filing
02 Jan 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Joanne M. Protano, Attorney-in-Fact

Key filing fact

Jose Carmona filed Form 4 for Rubius Therapeutics, Inc. on 01 Feb 2022.

Key facts

  • This page summarizes Jose Carmona's Form 4 filing for Rubius Therapeutics, Inc..
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 01 Feb 2022, 20:20.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RUBY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+143,750
Change %
Price
$0.000000
Shares after
143,750
Date
31 Jan 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
143,750
Exercise price
$6.75
Footnotes
F1
RUBY transaction Derivative

Restricted Stock Units

Award

Transaction value
$0
Shares
+34,500
Change %
Price
$0.000000
Shares after
34,500
Date
31 Jan 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
34,500
Exercise price
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Footnote F3

The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .